BUFETOLOL HYDROCHLORIDE

Possibly Marketed Outside US

Details

Stereochemistry	MIXED
Molecular Formula	C18H29NO4.ClH
Molecular Weight	359.888
Optical Activity	UNSPECIFIED
Defined Stereocenters	0 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CC(C)(C)NCC(O)COC1=C(OCC2CCCO2)C=CC=C1

InChI

InChIKey=DTAWWMIEZBHDDH-UHFFFAOYSA-N

InChI=1S/C18H29NO4.ClH/c1-18(2,3)19-11-14(20)12-22-16-8-4-5-9-17(16)23-13-15-7-6-10-21-15;/h4-5,8-9,14-15,19-20H,6-7,10-13H2,1-3H3;1H

HIDE SMILES / InChI

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/9502
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/international/adobiol.html and https://www.jstage.jst.go.jp/article/circj/80/3/80_CJ-66-0122/_pdf

Bufetolol is a β-adrenergic blocking agent. Bufetolol hydrochloride (a derivative of Bufetolol) is reported as an ingredient of Adobiol in Japan. It is used for the treatment of hypertension and hypertrophic cardiomyopathy.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Adrenergic receptor beta 89 Target ID: CHEMBL2094118 Sources: http://www.sciencedirect.com/science/article/pii/S006577430860994X	Antagonist 2849

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 575 Sources: http://www.ncbi.nlm.nih.gov/pubmed/6132016	Primary		Approved 8583	Adobiol Approved Use Indications: cardiovascular disorders
Hypertrophic cardiomyopathy 8 Sources: https://www.jstage.jst.go.jp/article/circj/80/3/80_CJ-66-0122/_pdf	Primary		Approved 8583	Adobiol Approved Use For the treatment of Hypertrophic cardiomyopathy

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.48 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400315_2123006F1030_1_090_1F.pdf#page=17	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		BUFETOLOL blood	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN

PubMed

Title	Date	PubMed
Effects of beta-adrenoceptor blocking agents of N-tertiary butyl derivatives on maximum upstroke velocity of action potential in guinea-pig papillary muscles.	1983-09	6138715
Possible significance of the pharmacological differentiation of beta-blocking agents in hemodynamic effects in essential hypertension.	1983-03	6132016

Patents

Sample Use Guides

In Vivo Use Guide

Daily dose approved in Japan for the treatment of hypertrophic cardiomyopathy - 15mg/day

Route of Administration: Oral

In Vitro Use Guide

Bufetolol (10(-4) M) additionally prolonged the time for 90% repolarization of the dog Purkinje fibres.

Name

Type

Language

BUFETOLOL HYDROCHLORIDE

Common Name

English

Y 6124

Preferred Name

English

BUFETOLOL HYDROCHLORIDE [JAN]

Common Name

English

Bufetolol hydrochloride [WHO-DD]

Common Name

English

BUFETOLOL HYDROCHLORIDE [MI]

Common Name

English

Y-6124

Code

English

1-TERT-BUTYLAMINO-3-(2-TETRAHYDROFURFURYLOXYPHENOXY)PROPAN-2-OL HYDROCHLORIDE

Systematic Name

English

2-PROPANOL, 1-((1,1-DIMETHYLETHYL)AMINO)-3-(2-((TETRAHYDRO-2-FURANYL)METHOXY)PHENOXY)-, HYDROCHLORIDE (1:1)

Systematic Name

English

BUFETOLOL HYDROCHLORIDE [MART.]

Common Name

English

BUFETOLOL HCL

Common Name

English

Code System Code Type Description

MERCK INDEX

m1045